Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor Cancer × Paclitaxel × Other solid neoplasm × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 25 Solid Tumors 12 Solid Tumor 10 Advanced Solid Tumors 9 Advanced Solid Tumor 5 Mesothelioma 3 Carcinoma, Non-Small-Cell Lung 3 Advanced Solid Tumours 3 Triple Negative Breast Neoplasms 2 Solid Tumor, Adult 2 Neoplasms 2 Mesothelioma, Malignant 2 Carcinoma, Renal Cell 2 Advanced Solid Tumour 2 Uterine Cervical Neoplasms 1 Unspecified Adult Solid Tumor - Protocol Specific 1 Unresectable Locally Advanced or Metastatic Solid Tumors 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor Cancer 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Retinoblastoma 1 Recurrent Malignant Solid Neoplasm 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 P1b: Advanced Solid Tumors 1

Interventions

ispinesib 2 trametinib 1 irinotecan sucrosofate 1 Vincristine 1 Temozolomide 1 TP protocol 1 Pemetrexed 1 Paclitaxel 1 PE regimen 1 Interleukin-18 1 Immunotherapy 1 Imatinib Mesylate 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06649448 2024-10-18

EF-001

Shandong Cancer Hospital and Institute

Phase NA Not yet recruiting

Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡